

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

ERYSENG suspension for injection for pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 2 ml contains:

### Active substance:

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,  
\* IE<sub>50%</sub> – Inhibition ELISA 50%.

> 3.34 log<sub>2</sub> IE<sub>50%</sub>\*

### Adjuvants:

Aluminium hydroxide  
DEAE-Dextran  
Ginseng

5.29 mg (aluminium)

### Excipients:

Qualitative composition of excipients and other constituents
Disodium phosphate dodecahydrate
Potassium chloride
Potassium dihydrogen phosphate
Simethicone
Sodium chloride
Sodium hydroxide
Water for injections

Whitish suspension.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Pigs.

### 3.2 Indications for use for each target species

For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by *Erysipelothrix rhusiopathiae*, serotype 1 and serotype 2.

Onset of immunity: three weeks after completion of the basic vaccination scheme.

Duration of immunity: six months.

### 3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance, to the adjuvants or to any of the excipients.

### 3.4 Special warnings

Vaccinate healthy animals only.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

None.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Pigs:

Very common (> 1 animal / 10 animals treated):	Injection site inflammation <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):	Elevated temperature <sup>2</sup>
Very rare (< 1 animal / 10 000 animals treated, including isolated reports):	Anaphylactic-type reaction <sup>3</sup>

<sup>1</sup>Mild to moderate inflammation at the injection site that typically resolves within 4 days but in some cases may persist for up to 12 days post-vaccination.

<sup>2</sup>A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours.

<sup>3</sup>An appropriate symptomatic treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

Can be used during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### 3.9 Administration routes and dosage

Intramuscular use.

Allow the vaccine to reach room temperature (15 °C – 25 °C) before administration.  
Shake well before use.

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

Basic vaccination:

Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3 – 4 weeks. The second injection should be administered 3 – 4 weeks before mating.

Revaccination:

A single injection should be given 2 – 3 weeks prior to each subsequent mating (approximately every 6 months).

**3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions other than those mentioned in section 3.6 were observed after the administration of a 2-fold vaccine dose.

**3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

**3.12 Withdrawal periods**

Zero days.

**4. IMMUNOLOGICAL INFORMATION**

**4.1 ATCvet code: QI09AB03.**

To stimulate the development of active immunity in pigs against *E. rhusiopathiae*.

**5. PHARMACEUTICAL PARTICULARS**

**5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

**5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging: use immediately.

**5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

#### **5.4 Nature and composition of immediate packaging**

Type I colourless glass vials of 20, 50 and 100 ml. The vials are closed with a rubber stopper and aluminium cap.

Polyethylene (PET) bottles of 20, 50, 100 and 250 ml.

##### Pack sizes:

Cardboard box with 1 glass vial of 10 doses (20 ml).

Cardboard box with 1 glass vial of 25 doses (50 ml).

Cardboard box with 1 glass vial of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 10 doses (20 ml).

Cardboard box with 1 PET bottle of 25 doses (50 ml).

Cardboard box with 1 PET bottle of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 125 doses (250 ml).

Not all pack sizes may be marketed.

#### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

#### **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

#### **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/14/166/001-007

#### **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 04/07/2014

#### **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{DD/MM/YYYY}

#### **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

**ANNEX II**

**OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box (20 ml, 50 ml, 100 ml, and 250 ml)

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

One dose (2 ml) contains:

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,

> 3.34 log<sub>2</sub> IE<sub>50</sub> %\*

\* IE<sub>50</sub> % – Inhibition ELISA 50 %.

**3. PACKAGE SIZE**

10 doses (20 ml)

25 doses (50 ml)

50 doses (100 ml)

125 doses (250 ml)

**4. TARGET SPECIES**

Pigs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/14/166/001 10 doses  
EU/2/14/166/002 25 doses  
EU/2/14/166/003 50 doses  
EU/2/14/166/004 10 doses  
EU/2/14/166/005 25 doses  
EU/2/14/166/006 50 doses  
EU/2/14/166/007 125 doses

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Bottles (100 ml and 250 ml) and vials (100 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

One dose (2 ml) contains:

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,

> 3.34 log<sub>2</sub> IE<sub>50</sub> %\*

\* IE<sub>50</sub>% – Inhibition ELISA 50 %.

**3. TARGET SPECIES**

Pigs

**4. ROUTES OF ADMINISTRATION**

Read the package leaflet before use.

Intramuscular use.

**5. WITHDRAWAL PERIODS**

Withdrawal period: Zero days.

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**7. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.

Do not freeze.

Protect from light.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

LABORATORIOS HIPRA, S.A.

**9. BATCH NUMBER**

Lot {number}

## **10. PACKAGE SIZE**

50 doses (100 ml)  
125 doses (250 ml)

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Bottles (20 ml, 50 ml) and vials (20 ml, 50 ml)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ERYSENG

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,

> 3.34 log<sub>2</sub> IE<sub>50</sub>%\*

\* IE<sub>50</sub>% – Inhibition ELISA 50%.

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use immediately.

**5. PACKAGE SIZE**

10 doses (20 ml)

25 doses (50 ml)

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

ERYSENG suspension for injection for pigs

### 2. Composition

Each dose of 2 ml contains:

#### Active substances:

Inactivated *Erysipelothrix rhusiopathiae*, strain R32E11,

> 3.34 log<sub>2</sub> IE<sub>50%</sub> \*

\* IE<sub>50%</sub> - Inhibition ELISA 50%.

#### Adjuvants:

Aluminium hydroxide

5.29 mg (aluminium)

Whitish suspension for injection.

### 3. Target species

Pigs.

### 4. Indications for use

For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by *Erysipelothrix rhusiopathiae*, serotype 1 and serotype 2.

Onset of immunity: three weeks after completion of the basic vaccination scheme.

Duration of immunity: six months.

### 5. Contraindications

Do not use in cases of hypersensitivity to the active substance, to the adjuvants or to any of the excipients.

### 6. Special warnings

#### Special warnings:

Vaccinate healthy animals only.

#### Special precautions for safe use in the target species:

None.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse reactions other than already mentioned under section “Adverse events” can be expected after the administration of a 2-fold vaccine dose.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

**7. Adverse events**

Pigs:

Very common (> 1 animal / 10 animals treated):
Injection site inflammation <sup>1</sup>
Common (1 to 10 animals / 100 animals treated):
Elevated temperature <sup>2</sup>
Very rare (< 1 animal / 10 000 animals treated, including isolated reports):
Anaphylactic-type reaction (severe allergic reaction) <sup>3</sup>

<sup>1</sup>Mild to moderate inflammation at the injection site that typically resolves within 4 days but in some cases may persist for up to 12 days post-vaccination.

<sup>2</sup>A transient increase in body temperature within the first 6 hours after vaccination, which spontaneously resolves within 24 hours.

<sup>3</sup>An appropriate symptomatic treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

**8. Dosage for each species, routes and method of administration**

Intramuscular use.

Administer one dose of 2 ml by intramuscular injection in the neck muscles according to the following schedule:

Basic vaccination:

Pigs from 6 months of age which have not been previously vaccinated with the product should be given two injections with an interval of 3 – 4 weeks. The second injection should be administered 3 – 4 weeks before mating.

Revaccination:

A single injection should be given 2 – 3 weeks prior to each subsequent mating (approximately every 6 months).

## **9. Advice on correct administration**

Allow the vaccine to reach room temperature (15 °C – 25 °C) before administration.  
Shake well before use.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**

Keep out of the sight and reach of children.  
Store and transport refrigerated (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and the cardboard box after Exp. The expiry date refers to the last day of that month.  
Shelf life after first opening the container: use immediately.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

Marketing authorisation numbers: EU/2/14/166/001 - 007

### Pack sizes:

Cardboard box with 1 glass vial of 10 doses (20 ml).  
Cardboard box with 1 glass vial of 25 doses (50 ml).  
Cardboard box with 1 glass vial of 50 doses (100 ml).

Cardboard box with 1 PET bottle of 10 doses (20 ml).  
Cardboard box with 1 PET bottle of 25 doses (50 ml).  
Cardboard box with 1 PET bottle of 50 doses (100 ml).  
Cardboard box with 1 PET bottle of 125 doses (250 ml).

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

LABORATORIOS HIPRA, S.A.  
Avda. la Selva, 135  
17170 AMER (Girona) SPAIN  
TEL: +34 972 43 06 60

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Local representatives and contact details to report suspected adverse reactions:

**België/Belgique/Belgien**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIUM  
Tel: +32 09 2964464

**Lietuva**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ISPANIJA  
Tel: +34 972 43 06 60

**Република България**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ИСПАНИЯ  
Тел: +34 972 43 06 60

**Luxembourg/Luxemburg**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIUM  
Tel: +32 09 2964464

**Česká republika**

HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Magyarország**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANYOLORSZÁG  
Tel: +34 972 43 06 60

**Danmark**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel: +34 972 43 06 60

**Malta**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANJA  
Tel: +34 972 43 06 60

**Deutschland**

HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**Eesti**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
HISPAANIA  
Tel: +34 972 43 06 60

**Ελλάδα**

HIPRA ΕΛΛΑΣ Α.Ε.  
Λεωφ. Αθηνών 80 & Μηριόνου 2-4,  
104 41 Κολωνός - ΑΘΗΝΑ - ΕΛΛΑΣ  
Τηλ: +30 210 4978660

**España**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPAÑA  
Tel: +34 972 43 06 60

**France**

HIPRA FRANCE  
7 rue Roland Garros, Batiment H  
44700 - Orvault -  
FRANCE  
Tél: +33 02 51 80 77 91

**Hrvatska**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANJOLSKA  
Tel: +34 972 43 06 60

**Ireland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60

**Ísland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPÁNN  
Sími: +34 972 43 06 60

**Nederland**

HIPRA BENELUX NV  
Nieuwewandeling 62  
9000 Gent  
BELGIUM  
Tel: +32 09 2964464

**Norge**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tlf: +34 972 43 06 60

**Österreich**

HIPRA DEUTSCHLAND GmbH  
Am Wehrhahn 28-30  
40211 Düsseldorf  
DEUTSCHLAND  
Tel: +49 211 698236 – 0

**Polska**

HIPRA POLSKA Sp.z.o.o.  
Ul. Wincentego Rzymowskiego 31  
02-697 Warszawa - POLSKA  
Tel: +48 22 642 33 06

**Portugal**

ARBUSET, Produtos Farmacêuticos e Sanitários  
De Uso Animal, Lda  
Portela de Mafra e Fontainha - Abrunheira  
2665 – 191 Malveira - PORTUGAL  
Tel:+351 219 663 450

**România**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIA  
Tel: +34 972 43 06 60

**Slovenija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ŠPANIIJA  
Tel: +34 972 43 06 60

**Slovenská republika**

HIPRA SLOVENSKO, s.r.o.  
Zochova 5,  
811 03 Bratislava,  
SLOVENSKO  
Tel: +421 02 32 335 223

**Italia**

Hipra Italia S.r.l.  
Enrico Mattei, 2  
25030 Coccaglio (BS)  
ITALIA  
Tel: +39 030 7241821

**Κύπρος**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ΙΣΠΑΝΙΑ  
Τηλ: +34 972 43 06 60

**Latvija**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPĀNIJA  
Tel. +34 972 43 06 60

**Suomi/Finland**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
ESPANJA  
Puh/Tel: +34 972 43 06 60

**Sverige**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPANIEN  
Tel. +34 972 43 06 60

**United Kingdom (Northern Ireland)**

LABORATORIOS HIPRA, S.A.  
Avda. La Selva 135  
17170 Amer (Girona)  
SPAIN  
Tel: +34 972 43 06 60